A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Phase 2 Active not recruiting 160 enrolled Hoffmann-La Roche

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).

Timeline

Start: 2025-04-01
Primary completion: 2026-07-22
Completion: 2027-02-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Afimkibart	Monoclonal antibody	—	Subcutaneous

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Summary

Timeline

Drugs

Indications